<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="tfr2" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">tfr2</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">TFR2</italic>-Related Hereditary Hemochromatosis</title>
        <alt-title alt-title-type="alt-title">Synonym: Type 3 Hereditary Hemochromatosis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Camaschella</surname>
            <given-names>Clara</given-names>
          </name>
          <degrees>MD</degrees>
          <email>Camaschella.clara@hsr.it</email>
          <aff>Professor, Internal Medicine <break/>Universita Vita-Salute <break/>Istituto Scientifico San Raffaele <break/>Milano, Italy</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Roetto</surname>
            <given-names>Antonella</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>Antonella.roetto@unito.it</email>
          <aff>University of Torino <break/>Azienda Ospedaliera San Luigi <break/>Torino, Italy</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2005-08-29" date-type="created">
          <day>29</day>
          <month>8</month>
          <year>2005</year>
        </date>
        <date iso-8601-date="2011-06-09" date-type="updated">
          <day>9</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date iso-8601-date="2008-08-05" date-type="revised">
          <day>5</day>
          <month>8</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="tbc1d24-dis" document-type="chapter">
<italic toggle="yes">TBC1D24</italic>-Related Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="tk2-mtddepl" document-type="chapter"><italic toggle="yes">TK2</italic>-Related Mitochondrial DNA Depletion Syndrome, Myopathic Form</related-object>
      <abstract id="tfr2.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC) is characterized by increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs. Age of onset is earlier than in <italic toggle="yes">HFE</italic>-associated HHC. Some individuals present in the second decade and others present as adults with fatigue and arthralgia and/or organ involvement including liver cirrhosis, diabetes mellitus, and arthropathy. In other individuals, <italic toggle="yes">TFR2</italic>-HHC may not be progressive even if untreated.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">TFR2</italic>-HHC in individuals with clinical symptoms and/or biochemical evidence of iron overload is typically based on serum transferrin-iron saturation (&#x0003e;45% in men and women) and serum ferritin concentration (usually &#x0003e;200 &#x000b5;g/L in females and &#x0003e;300 &#x000b5;g/L in males) as well as histologic assessment of hepatic iron stores on liver biopsy. <italic toggle="yes">TFR2</italic> is the only gene in which mutations are known to cause <italic toggle="yes">TFR2</italic>-HHC.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Removal of excess iron by routine phlebotomy to maintain serum ferritin concentration at 50 ng/mL or lower and transferrin-iron saturation below 50%; lifelong hormone replacement therapy for hypogonadism; gonadotropins for fertility/pregnancy; nonsteroidal anti-inflammatory drugs (NSAIDs) and joint replacement for arthropathy; diuretics; routine treatment for cardiac failure and diabetes mellitus.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Routine phlebotomy: see <italic toggle="yes">Treatment of manifestations</italic>.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitoring serum ferritin concentration every three to four months once serum ferritin concentration is lower than 50 ng/mL.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Avoid medicinal iron, mineral supplements, excess vitamin C, uncooked seafood; restrict alcohol intake for those with liver involvement.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the pathogenic variants in the family are known, molecular genetic testing of at-risk relatives to allow early diagnosis and treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">TFR2</italic>-HHC is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic and do not have abnormalities of iron parameters. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if both pathogenic variants have been identified in the family. Requests for prenatal testing for conditions such as <italic toggle="yes">TFR2</italic>-HHC that do not affect intellect and have effective treatment available are not common.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="tfr2.Diagnosis">
        <title>Diagnosis</title>
        <sec id="tfr2.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC) should be suspected in any individual with findings of iron overload (including hepatomegaly, hepatic cirrhosis, diabetes mellitus, cardiomyopathy, hypogonadism, arthritis [especially if involving the metacarpophalangeal joint], and progressive increase in skin pigmentation) in whom <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object> has been excluded.</p>
          <p>More typically, individuals present with either of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Early clinical findings of hereditary hemochromatosis (including vague nonspecific symptoms, e.g., abdominal pain, fatigue, arthralgia, decreased libido)</p>
            </list-item>
            <list-item>
              <p>More frequently, biochemical evidence of iron overload in routinely used panels that include serum transferrin-iron saturation and serum concentrations of iron and ferritin</p>
            </list-item>
          </list>
          <p>Note: No specific diagnostic guidelines are available for <italic toggle="yes">TFR2</italic>-related hemochromatosis; however, guidelines/recommendations of scientific societies or experts for <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object> are available (see following and references cited).</p>
        </sec>
        <sec id="tfr2.Testing">
          <title>Testing</title>
          <p>Diagnosis of <italic toggle="yes">TFR2</italic>-HHC is suspected in individuals with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Transferrin saturation</bold> higher than 45%. Normal range is between 20% and 35% saturation in both sexes.</p>
            </list-item>
            <list-item>
              <p><bold>Serum ferritin concentration</bold> usually higher than 200 &#x000b5;g/L in females and higher than 300 &#x000b5;g/L in males.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Normal ranges:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Children and adolescents: 15-150 &#x000b5;g/L</p>
                    </list-item>
                    <list-item>
                      <p>Adult males: 20-300 &#x000b5;g/L</p>
                    </list-item>
                    <list-item>
                      <p>Adult females: 20-200 &#x000b5;g/L</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>Note: The same biochemical iron parameters are used in diagnosis of <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis [<xref ref-type="bibr" rid="tfr2.REF.pietrangelo.2010.393">Pietrangelo 2010</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Liver biopsy.</bold> Findings on liver biopsy have been reported in a few individuals with <italic toggle="yes">TFR2</italic>-HHC [<xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.pietrangelo.2005.470">Pietrangelo et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.hsiao.2007.303">Hsiao et al 2007</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>]. Liver biopsy is used to assess:</p>
          <list list-type="bullet">
            <list-item>
              <p>Histology; fibrosis or cirrhosis</p>
            </list-item>
            <list-item>
              <p>Liver iron concentration (LIC)</p>
            </list-item>
            <list-item>
              <p>Distribution of iron storage. Increased iron deposition in the hepatocytes and a decreasing gradient of iron stores are observed from portal to centrolobular areas [<xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>], as in <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis).</p>
            </list-item>
          </list>
          <p><bold>Imaging.</bold> Noninvasive techniques including MRI [<xref ref-type="bibr" rid="tfr2.REF.gandon.2004.357">Gandon et al 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.st_pierre.2005.855">St Pierre et al 2005</xref>] and SQUID developed to quantitate liver iron concentration have been applied to <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis [<xref ref-type="bibr" rid="tfr2.REF.carneiro.2004.85">Carneiro et al 2004</xref>] but rarely to <italic toggle="yes">TFR2</italic>-HHC [<xref ref-type="bibr" rid="tfr2.REF.piperno.2004.359">Piperno et al 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>].</p>
          <sec id="tfr2.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">TFR2</italic> is the only gene in which pathogenic variants are known to cause <italic toggle="yes">TFR2</italic>-HHC.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Targeted analysis for pathogenic variants.</bold> A panel of four pathogenic variants (see <xref ref-type="table" rid="tfr2.T.summary_of_molecular_genetic_test">Table 1</xref>) identifies variants in fewer than 50% of individuals known to have <italic toggle="yes">TFR2</italic>-HHC.</p>
              </list-item>
              <list-item>
                <p><bold>Sequence analysis.</bold> The variant detection frequency by sequence analysis is higher than 98% [<xref ref-type="bibr" rid="tfr2.REF.biasiotto.2003.1981">Biasiotto et al 2003</xref>].</p>
              </list-item>
            </list>
            <table-wrap id="tfr2.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">TFR2</italic>-Related Hereditary Hemochromatosis</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">TFR2</italic>
                    </td>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants</td>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">c.88_89insC</xref>, <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">c.313C&#x0003e;T</xref>, <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">c.515T&#x0003e;A</xref>, <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">c.750C&#x0003e;G</xref>, <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">c.1861_1872del12</xref></td>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;50%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_tfr2.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;98%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tfr2.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="thctd" object-id="thctd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="tfr2.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="tfr2.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="tfr2.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="tfr2.TF.1.4">
                  <label>4. </label>
                  <p>Data are from the Italian population [Author, personal observation].</p>
                </fn>
                <fn id="tfr2.TF.1.5">
                  <label>5. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="tfr2.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>Confirmation of the diagnosis in a proband.</bold> In an individual with a clinical diagnosis of hemochromatosis and/or increased iron at liver biopsy (or MRI) and/or a family history of hemochromatosis <bold>AND</bold> no identifiable <italic toggle="yes">HFE</italic> pathogenic variants, molecular genetic testing for <italic toggle="yes">TFR2</italic> pathogenic variants is appropriate.</p>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for an autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="tfr2.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="tfr2.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC) is characterized by deregulated, increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs [<xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al 2000</xref>, <xref ref-type="bibr" rid="tfr2.REF.camaschella.2009.140">Camaschella &#x00026; Poggiali 2009</xref>].</p>
          <p>The age of onset in <italic toggle="yes">TFR2</italic>-HHC is earlier than in <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object>. One child age 3.5 years had transferrin saturation and serum ferritin concentration that were increased for age [<xref ref-type="bibr" rid="tfr2.REF.piperno.2004.359">Piperno et al 2004</xref>]. Some individuals present with signs of iron overload in the second decade [<xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.hattori.2003.154">Hattori et al 2003</xref>, <xref ref-type="bibr" rid="tfr2.REF.le_gac.2004.674">Le Gac et al 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.piperno.2004.359">Piperno et al 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>, <xref ref-type="bibr" rid="tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami et al 2008</xref>]. Others present as adults with abnormal serum iron studies or fatigue and arthralgia and/or signs of organ involvement (liver cirrhosis, diabetes, arthropathy) [<xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.hattori.2003.154">Hattori et al 2003</xref>, <xref ref-type="bibr" rid="tfr2.REF.koyama.2005.302">Koyama et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>]. Severe joint involvement has been reported [<xref ref-type="bibr" rid="tfr2.REF.ricerca.2009.494">Ricerca et al 2009</xref>].</p>
          <p>Disease progression is slower than in <related-object link-type="booklink" source-id="gene" document-id="jh" document-type="chapter">juvenile hereditary hemochromatosis</related-object>, even in untreated individuals [<xref ref-type="bibr" rid="tfr2.REF.de_gobbi.2002.973">De Gobbi et al 2002</xref>]. Even untreated, <italic toggle="yes">TFR2</italic>-HHC may not be progressive [<xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>].</p>
          <p>When <italic toggle="yes">TFR2</italic>-HHC is progressive, complications can include cirrhosis, hypogonadotropic hypogonadism, and arthritis. Cardiomyopathy and diabetes mellitus are rare [<xref ref-type="bibr" rid="tfr2.REF.riva.2004.370">Riva et al 2004</xref>] and hepatocellular carcinoma has not been observed in the limited number of affected individuals reported to date.</p>
          <p>Most individuals reported to date have been of Italian or Japanese ancestry. Individuals of Japanese ancestry were older at diagnosis than those of Italian ancestry and had hepatic iron loading; a few middle-aged Japanese males had cirrhosis [<xref ref-type="bibr" rid="tfr2.REF.hattori.2003.154">Hattori et al 2003</xref>, <xref ref-type="bibr" rid="tfr2.REF.koyama.2005.302">Koyama et al 2005</xref>].</p>
        </sec>
        <sec id="tfr2.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The limited number of individuals reported and the private nature of the pathogenic variants do not permit genotype-phenotype correlations.</p>
          <p>Presence of the p.His63Asp allele of <italic toggle="yes">HFE</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000401.1">NP_000401.1</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000410.3">NM_000410.3</ext-link>) has been described in individuals with <italic toggle="yes">TFR2</italic>-HHC [<xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al 2000</xref>, <xref ref-type="bibr" rid="tfr2.REF.piperno.2004.359">Piperno et al 2004</xref>]; however, the contribution of the p.His63Asp allele to the <italic toggle="yes">TFR2</italic>-related iron overload is unclear.</p>
          <p>Inheritance of compound heterozygosity for the <italic toggle="yes">HFE</italic> pathogenic variants p.Cys282Tyr (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000401.1">NP_000401.1</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000410.3">NM_000410.3</ext-link>:c. 845G&#x0003e;A) and p.His63Asp and homozygosity for the <italic toggle="yes">TFR2</italic> pathogenic variant <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">p.Gln317Ter</xref> produced a phenotype of juvenile hemochromatosis in a single family [<xref ref-type="bibr" rid="tfr2.REF.pietrangelo.2005.470">Pietrangelo et al 2005</xref>].</p>
        </sec>
        <sec id="tfr2.Penetrance">
          <title>Penetrance</title>
          <p>The penetrance of <italic toggle="yes">TFR2</italic>-HHC is less than 100%. In a family reported in the study by <xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al [2001]</xref>, one middle-aged female homozygous for the <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">p.Arg30ProfsTer31</xref> pathogenic variant had no evidence of clinical disease; a second female had no signs of iron overload, and in fact had iron deficiency.</p>
        </sec>
        <sec id="tfr2.Nomenclature">
          <title>Nomenclature</title>
          <p><italic toggle="yes">TFR2</italic>-HHC is also known as hemochromatosis type 3 (HFE3); however, the term HFE3 seems inappropriate because <italic toggle="yes">HFE</italic> has no role in <italic toggle="yes">TFR2</italic>-HHC.</p>
        </sec>
        <sec id="tfr2.Prevalence">
          <title>Prevalence</title>
          <p><italic toggle="yes">TFR2</italic>-HHC is rare. Fewer than 30 affected individuals have been reported worldwide, most commonly in Japan, Portugal, and Italy.</p>
          <p>Single families from France [<xref ref-type="bibr" rid="tfr2.REF.le_gac.2004.674">Le Gac et al 2004</xref>], Italy [<xref ref-type="bibr" rid="tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami et al 2008</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>], and Portugal [<xref ref-type="bibr" rid="tfr2.REF.mattman.2002.1075">Mattman et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.mendes.2009.229">Mendes et al 2009</xref>] have been reported. One case was reported in Taiwan [<xref ref-type="bibr" rid="tfr2.REF.hsiao.2007.303">Hsiao et al 2007</xref>].</p>
          <p>Screening for <italic toggle="yes">TFR2</italic> pathogenic variants on a large scale is not available.</p>
          <list list-type="bullet">
            <list-item>
              <p>In Italy screening for the first identified <italic toggle="yes">TFR2</italic> pathogenic variant (<xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">p.Tyr250Ter</xref>) among a small cohort of blood donors with increased transferrin saturation revealed a single p.Tyr250Ter heterozygote [<xref ref-type="bibr" rid="tfr2.REF.de_gobbi.2001.243">De Gobbi et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>In Portugal a recent study of individuals with iron overload but without pathogenic variants in <italic toggle="yes">HFE</italic> identified three <italic toggle="yes">TFR2</italic> variants [<xref ref-type="bibr" rid="tfr2.REF.mendes.2009.229">Mendes et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>Screening of individuals with non-<italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis worldwide did not identify the p.Tyr250Ter pathogenic variant in persons of northern European background [<xref ref-type="bibr" rid="tfr2.REF.aguilarmartinez.2001a.290">Aguilar-Martinez et al 2001a</xref>, <xref ref-type="bibr" rid="tfr2.REF.aguilarmartinez.2001b.836">Aguilar-Martinez et al 2001b</xref>, <xref ref-type="bibr" rid="tfr2.REF.barton.2001.279">Barton et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>In Japan, where hemochromatosis is rare and heterogeneous, it has been proposed that <italic toggle="yes">TFR2</italic>-HHC is the most frequent form of hereditary hemochromatosis [<xref ref-type="bibr" rid="tfr2.REF.hayashi.2006.1107">Hayashi et al 2006</xref>]; however, studies are limited.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="tfr2.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with pathogenic variants in <italic toggle="yes">TFR2</italic>.</p>
      </sec>
      <sec id="tfr2.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC, sometimes called type 3 HHC) needs to be distinguished from other primary iron overload disorders as well as from secondary iron overload disorders. No specific studies have evaluated the percentage of <italic toggle="yes">TFR2</italic> pathogenic variants detected in individuals with non-<italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis.</p>
        <sec id="tfr2.Primary_Iron_Overload_Disorders">
          <title>Primary Iron Overload Disorders</title>
          <p>Primary overload disorders are characterized by increased absorption of iron from a normal diet.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><bold><italic toggle="yes">HFE</italic>-related hereditary hemochromatosis</bold></related-object> (hemochromatosis type 1) is the most common form. <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis is characterized by excessive storage of iron, particularly in the liver, skin, pancreas, heart, joints, and pituitary, resulting in <related-object link-type="booklink" source-id="gene" document-id="kms" document-type="chapter">hypogonadotropic hypogonadism</related-object>. Without therapy, males may develop symptoms between ages 40 and 60 years and females after menopause. Hepatic fibrosis or cirrhosis may occur in untreated individuals after age 40 years. A large fraction of homozygotes (98% in some series) [<xref ref-type="bibr" rid="tfr2.REF.asberg.2001.1108">Asberg et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.beutler.2002.211">Beutler et al 2002</xref>] for pathogenic variants in this gene do not develop clinical symptoms (i.e., penetrance is low). Inheritance is autosomal recessive.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="jh" document-type="chapter"><bold>Juvenile hereditary hemochromatosis</bold></related-object> (sometimes called type 2 HHC) has an earlier age of onset and more severe clinical manifestations than <italic toggle="yes">HFE</italic>-related hereditary hemochromatosis. Two related genes (hence, two clinically indistinguishable "subtypes") have been identified: type 2A is caused by pathogenic variants in <italic toggle="yes">HJV</italic> encoding hemojuvelin; type 2B is caused by pathogenic variants in <italic toggle="yes">HAMP</italic>. Onset of severe iron overload typically occurs in the first to third decades of life. Males and females are equally affected. Prominent clinical features include hypogonadotropic hypogonadism, cardiomyopathy, arthropathy, and liver fibrosis or cirrhosis. Hepatocellular cancer has not been reported. The main cause of death is cardiac-related disease. If juvenile hemochromatosis is detected early enough and if blood is removed regularly through the process of phlebotomy to achieve iron depletion, morbidity and mortality are greatly reduced. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="tfr2.REF.roetto.1999.1388">Roetto et al 1999</xref>, <xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al 2000</xref>, <xref ref-type="bibr" rid="tfr2.REF.de_gobbi.2002.973">De Gobbi et al 2002</xref>].</p>
          <p><bold>Ferroportin-related hereditary hemochromatosis</bold> (hemochromatosis type 4) is caused by pathogenic variants in <italic toggle="yes">SLC40A1,</italic> or solute carrier family 40 (iron-regulated transporter) member 1, which encodes ferroportin. Onset is late. Unlike all other varieties of hemochromatosis, iron storage in most cases affects reticuloendothelial rather than parenchymal cells [<xref ref-type="bibr" rid="tfr2.REF.montosi.2001.619">Montosi et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.njajou.2001.213">Njajou et al 2001</xref>]. Inheritance is autosomal dominant.</p>
          <p>Recently, two types of ferroportin disease have been recognized.</p>
          <list list-type="bullet">
            <list-item>
              <p>The more common &#x0201c;ferroportin disease type A&#x0201d; is caused by pathogenic variants that reduce the iron export from macrophages resulting in macrophage iron accumulation and low-normal transferrin saturation [<xref ref-type="bibr" rid="tfr2.REF.schimanski.2005.4096">Schimanski et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>The less common &#x0201c;ferroportin disease type B&#x0201d; is caused by hepcidin-resistant pathogenic variants that permit continued export of iron from macrophages resulting in disease that resembles <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis with high transferrin saturation and iron in hepatocytes [<xref ref-type="bibr" rid="tfr2.REF.drakesmith.2005.1092">Drakesmith et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.wallace.2007.4690">Wallace &#x00026; Subramaniam 2007</xref>].</p>
            </list-item>
            <list-item>
              <p>Some persons have an intermediate phenotype with a mixed pattern of liver iron accumulation.</p>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="acp" document-type="chapter"><bold>Aceruloplasminemia</bold></related-object> is characterized by iron accumulation in the brain and the visceral organs, manifest as retinal degeneration, diabetes mellitus, and neurologic disease (movement disorders and ataxia) in individuals older than age 25 years. Early treatment with iron chelators can diminish iron accumulation and ameliorate symptoms. Aceruloplasminemia is caused by the complete lack of ceruloplasmin ferroxidase activity resulting from pathogenic variants in <italic toggle="yes">CP</italic>, which encodes ceruloplasmin. Inheritance is autosomal recessive.</p>
          <p><bold>African iron overload</bold> was originally described in Africans who drink a traditional beer brewed in non-galvanized steel drums. The disease does not develop in all beer drinkers, suggesting the existence of a genetic susceptibility. A missense change (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_055400.1">NP_055400.1</ext-link>:p.Gln248His; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_014585.5">NM_014585.5</ext-link>:c.744G&#x0003e;T) in <italic toggle="yes">SLC40A1</italic> encoding ferroportin has been reported in Africans and African Americans with iron overload by independent groups [<xref ref-type="bibr" rid="tfr2.REF.beutler.2003.305">Beutler et al 2003</xref>, <xref ref-type="bibr" rid="tfr2.REF.gordeuk.2003.299">Gordeuk et al 2003</xref>], but the functional effect of this pathogenic variant in vitro is controversial [<xref ref-type="bibr" rid="tfr2.REF.drakesmith.2005.1092">Drakesmith et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.mcnamara.2005.1855">McNamara et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.barton.2007.206">Barton et al 2007</xref>]. In the large HEIRS study the association of increased serum ferritin concentration and the polymorphism was found only in males [<xref ref-type="bibr" rid="tfr2.REF.rivers.2007.247">Rivers et al 2007</xref>].</p>
          <p>In <bold>neonatal hemochromatosis</bold> iron overload occurs in the fetus, likely secondary to different causes. At birth, liver failure dominates the clinical picture. The disease is extremely severe, often fatal, unless liver transplantation is performed. Inheritance is unknown. Recently, an immunologic pathogenesis has been proposed for recurrent cases because treatment of at-risk pregnancies with high-dose IV IGg resulted in significant improvement of the outcome [<xref ref-type="bibr" rid="tfr2.REF.whitington.2004.1690">Whitington &#x00026; Hibbard 2004</xref>].</p>
        </sec>
        <sec id="tfr2.Secondary_Iron_Overload_Disorders">
          <title>Secondary Iron Overload Disorders</title>
          <p>Secondary iron overload disorders include iron excess resulting from different conditions. The most severe disorders result from transfusions for chronic anemia such as <related-object link-type="booklink" source-id="gene" document-id="b-thal" document-type="chapter">beta-thalassemia</related-object> or <related-object link-type="booklink" source-id="gene" document-id="sickle" document-type="chapter">sickle cell disease</related-object>. Secondary iron overload may result from ingested iron in foods, cookware, and medicines, as well as parenteral iron from iron injections.</p>
          <p>This group also includes a range of liver diseases associated with parenchymal liver disease (e.g., alcoholic liver disease, acute viral hepatitis or chronic hepatitis C, neoplasia, <related-object link-type="booklink" source-id="gene" document-id="porphyria-ct" document-type="chapter">porphyria cutanea tarda</related-object>) and inflammatory disorders such as rheumatoid arthritis (which are questionable because inflammatory disorders are not true iron-loading disorders).</p>
        </sec>
      </sec>
      <sec id="tfr2.Management">
        <title>Management</title>
        <sec id="tfr2.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with <italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC), the following are recommended (based on recommendations for <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object>):</p>
          <list list-type="bullet">
            <list-item>
              <p>Liver biopsy for evaluation of abnormal liver function tests and establishing prognosis when serum ferritin concentration is greater than 1000 ng/mL and/or when hepatomegaly is present [<xref ref-type="bibr" rid="tfr2.REF.guyader.1998.929">Guyader et al 1998</xref>]</p>
            </list-item>
            <list-item>
              <p>Serum concentration of gonadotropins (FSH and LH) to assess pituitary function. Depending on the results, a GnRH stimulation test may be necessary.</p>
            </list-item>
            <list-item>
              <p>Serum concentration of testosterone to assess testicular function; serum concentration of estradiol to assess ovarian function</p>
            </list-item>
            <list-item>
              <p>Radiographs of the affected joint(s) to assess persistent arthralgia or arthropathy</p>
            </list-item>
            <list-item>
              <p>Cardiac evaluation (ECG and echocardiography) for all symptomatic individuals and those with severe iron overload (ferritin &#x0003e;1000 ng/mL)</p>
            </list-item>
            <list-item>
              <p>Screening for diabetes mellitus by fasting serum glucose concentration and oral glucose tolerance test (OGTT)</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfr2.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following recommendations are based on guidelines proposed for <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object> in Europe [<xref ref-type="bibr" rid="tfr2.REF.european_association_for_the_study_of_the_liver.2010.3">European Association for the Study of the Liver 2010</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>) and an expert review [<xref ref-type="bibr" rid="tfr2.REF.adams.2010.317">Adams &#x00026; Barton 2010</xref>]. However, it should be emphasized that since <italic toggle="yes">TFR2</italic>-HHC is rare and may progress differently from <italic toggle="yes">HFE</italic>-associated hemochromatosis, individual treatment is important.</p>
          <p>Individuals with increased serum ferritin concentration should be treated by the same protocol as for <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis.</p>
          <p><bold>Therapeutic phlebotomy.</bold> Periodic phlebotomy (i.e., removal of a unit of blood) is a simple, inexpensive, safe, and effective way to remove excess iron. Each unit of blood (400-500 mL) with a hematocrit of 40% contains approximately 160-200 mg of iron.</p>
          <p>The usual therapy is weekly phlebotomy; however, twice weekly phlebotomy may be useful initially to accelerate iron depletion. On average, men require removal of twice as many units of blood as women.</p>
          <p>Weekly phlebotomy is carried out until the serum ferritin concentration is 100 ng/mL or lower. Serum ferritin concentration should be measured following each phlebotomy or every other phlebotomy [<xref ref-type="bibr" rid="tfr2.REF.adams.2010.317">Adams &#x00026; Barton 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Once the serum ferritin concentration is approximately 50 ng/mL, monitoring serum ferritin concentration every three to four months is adequate.</p>
            </list-item>
            <list-item>
              <p>If the serum ferritin concentration is 50 ng/mL or higher despite a significant reduction in hematocrit, phlebotomies need to be spaced further apart.</p>
            </list-item>
          </list>
          <p>Note: Although experience is limited because of the small number of affected individuals identified worldwide, it should be noted that transferrin saturation remains high in <italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis when serum ferritin concentration is low (&#x0003c;50 ng/mL), even after intensive phlebotomy [<xref ref-type="bibr" rid="tfr2.REF.girelli.2011.500">Girelli et al 2011</xref>; Camaschella &#x00026; Roetto, unpublished observation].</p>
          <p><bold>Maintenance therapy.</bold> The goal is to maintain serum ferritin concentration around 50 ng/mL and transferrin-iron saturation below 50%. Phlebotomy to prevent reaccumulation of iron is performed about every three to four months for men and once or twice a year for women.</p>
          <p><bold>Iron chelation therapy</bold> is not recommended unless an individual has an elevated serum ferritin concentration and concomitant anemia that makes therapeutic phlebotomy impossible. Iron chelators such as subcutaneous desferrioxamine are used as a first choice in case of concomitant anemia [<xref ref-type="bibr" rid="tfr2.REF.riva.2004.370">Riva et al 2004</xref>] or cardiac dysfunction.</p>
          <p>Note: At present, oral iron chelators are not available to treat hemochromatosis. However, a phase I/II trial has been completed with daily administration of deferasirox in persons with newly diagnosed <italic toggle="yes">HFE</italic>-HHC with iron overload and without evidence of liver cirrhosis. The trial demonstrated that treatment is feasible, safe, and effective; side effects were mostly related to the GI tract [<xref ref-type="bibr" rid="tfr2.REF.phatak.2010.1671">Phatak et al 2010</xref>].</p>
          <p>
            <bold>Treatment of clinical complications</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Cirrhosis</bold> should be treated and followed up as in other conditions. Although cirrhosis is not reversible by phlebotomy, individuals with cirrhosis benefit from iron removal in that it reduces the risk of hepatocellular cancer.</p>
            </list-item>
            <list-item>
              <p><bold>Hypogonadism</bold> is irreversible and requires lifelong hormone replacement therapy in males and females. Use of gonadotropins has successfully restored fertility and induced pregnancy in women who have been treated for other forms of hemochromatosis.</p>
            </list-item>
            <list-item>
              <p><bold>Arthropathy</bold> requires nonsteroidal anti-inflammatory drugs (NSAIDs) and is barely influenced by phlebotomy. In some cases, joint replacement has been performed.</p>
            </list-item>
            <list-item>
              <p><bold>Cardiac failure</bold> is treated with diuretics, ACE inhibitors, cardiac glycosides, and iron chelation by intravenous or subcutaneous deferioxamine.</p>
            </list-item>
            <list-item>
              <p><bold>Diabetes mellitus</bold> may require lifelong insulin treatment. Iron removal may improve control of diabetes mellitus but cannot reestablish normal glucose metabolism.</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfr2.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>In affected individuals with increased serum ferritin concentration, prevention of primary manifestations is accomplished by weekly phlebotomy to deplete iron stores (see <xref ref-type="sec" rid="tfr2.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
        </sec>
        <sec id="tfr2.Surveillance">
          <title>Surveillance</title>
          <p>Once the serum ferritin concentration is around 50 ng/mL, monitoring serum ferritin concentration every three to four months is adequate.</p>
          <p>Although hepatocellular carcinoma has not been reported in individuals with <italic toggle="yes">TFR2</italic>-associated hereditary hemochromatosis, surveillance for its development should be performed in persons with cirrhosis by monitoring liver ultrasound examinations and serum concentrations of alpha-fetoprotein, as in persons with cirrhosis with <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis.</p>
        </sec>
        <sec id="tfr2.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medicinal iron</p>
            </list-item>
            <list-item>
              <p>Mineral supplements</p>
            </list-item>
            <list-item>
              <p>Excess vitamin C</p>
            </list-item>
            <list-item>
              <p>Uncooked seafood (because of the risk of infection from microorganisms thriving under conditions of excess iron)</p>
            </list-item>
          </list>
          <p>For those with hepatic involvement, alcohol intake should be restricted because it increases iron absorption and is toxic to the hepatocytes.</p>
        </sec>
        <sec id="tfr2.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the pathogenic variants in the family are known, it is appropriate to offer molecular genetic testing to at-risk relatives to allow early diagnosis and treatment.</p>
          <p>See <xref ref-type="sec" rid="tfr2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="tfr2.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Women with hemochromatosis do not need treatment during pregnancy because the fetal utilization of maternal iron effectively reduces the mother&#x02019;s iron load during pregnancy.</p>
        </sec>
        <sec id="tfr2.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="tfr2.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="tfr2.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis (<italic toggle="yes">TFR2</italic>-HHC) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="tfr2.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes and thus carry one mutant allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and do not have abnormalities of iron parameters.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and do not have abnormalities of iron parameters.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with <italic toggle="yes">TFR2</italic>-HHC are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">TFR2</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="tfr2.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing using molecular genetic testing for at-risk family members is possible once the pathogenic variants have been identified in the family.</p>
          <p>Carrier testing using biochemical testing is not possible because iron parameters are normal in heterozygotes.</p>
        </sec>
        <sec id="tfr2.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="tfr2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="tfr2.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variants have been identified in the family, prenatal diagnosis for pregnancies at increased risk may be available from a laboratory offering either testing for the gene/disease or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions which (like <italic toggle="yes">TFR2</italic>-HHC) do not affect intellect and have effective treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="tfr2.Resources">
        <title>Resources</title>
      </sec>
      <sec id="tfr2.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="tfr2.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">TFR2</italic>-encoded protein is highly expressed in the hepatocytes and its function is likely related to the hepcidin pathway that regulates iron homeostasis.</p>
          <p>The hepatic peptide hepcidin (encoded by <italic toggle="yes">HAMP</italic>) is a circulating hormone that regulates the absorption of dietary iron from the duodenum. Hepcidin expression is inappropriately decreased in hereditary hemochromatosis and is abnormally increased in the anemia of chronic diseases. Other hepatic proteins essential for normal iron homeostasis, including HFE, transferrin receptor protein 2 (TfR2), and hemojuvelin, function at least in part by modulating the expression of hepcidin [<xref ref-type="bibr" rid="tfr2.REF.hentze.2010.24">Hentze et al 2010</xref>].</p>
          <p>Individuals with homozygous <italic toggle="yes">TFR2</italic> pathogenic variants have increased intestinal iron absorption that causes iron overload. Low/absent levels of urinary hepcidin have been reported in <italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis [<xref ref-type="bibr" rid="tfr2.REF.nemeth.2005.1803">Nemeth et al 2005</xref>], suggesting that <italic toggle="yes">TFR2</italic> is a modulator of hepcidin. A time course of serum hepcidin after a single dose of oral iron in two individuals homozygous for a <italic toggle="yes">TFR2</italic> pathogenic variant revealed absence of hepcidin response [<xref ref-type="bibr" rid="tfr2.REF.girelli.2011.500">Girelli et al 2011</xref>]. A similar finding of down-regulation (or lack of up-regulation following iron loading) of mRNA of hepcidin in liver has been documented in mice with inactive <italic toggle="yes">Tfr2</italic> [<xref ref-type="bibr" rid="tfr2.REF.kawabata.2005.376">Kawabata et al 2005</xref>, <xref ref-type="bibr" rid="tfr2.REF.wallace.2005.980">Wallace et al 2005</xref>].</p>
          <p><bold>Benign allelic variants.</bold>
<italic toggle="yes">TFR2</italic> is 2471 bp long and consists of 18 exons. There are two main alternatively spliced variants (see <xref ref-type="fig" rid="tfr2.F1">Figure 1</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>Alpha, corresponding to transcription of all exons. Alpha-<italic toggle="yes">TFR2</italic> is prevalently and highly expressed in hepatocytes. Two alpha-<italic toggle="yes">TFR2</italic> cDNAs of 2.9 and 2.3 kb are recognized. The first (Genbank accession <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=3135305">AF053356</ext-link>) lacks 81 nucleotides in exon 8 and is 18 nucleotides longer in exon 18 [<xref ref-type="bibr" rid="tfr2.REF.glockner.1998.1060">Glockner et al 1998</xref>] when compared to the second (Genbank accession <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=5596369">AF067864</ext-link>) [<xref ref-type="bibr" rid="tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</xref>].</p>
            </list-item>
            <list-item>
              <p>Beta, which has an in-frame transcription start site in exon 4 [<xref ref-type="bibr" rid="tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</xref>]. Beta-<italic toggle="yes">TFR2</italic> cDNA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001206855.1">NM_001206855.1</ext-link>) lacks exons 1-3 and has 142 additional bases at its 5' end. Beta <italic toggle="yes">TFR2</italic> is expressed ubiquitously at very low levels. Based on animal models, it has been proposed that the beta form (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001193784.1">NP_001193784.1</ext-link>) has a role in regulating iron export in the spleen [<xref ref-type="bibr" rid="tfr2.REF.roetto.2010.3382">Roetto et al 2010</xref>] (see <bold>Normal gene product</bold>).</p>
            </list-item>
          </list>
          <p>Several exonic normal DNA variants have been described (see <xref ref-type="fig" rid="tfr2.F1">Figure 1</xref>); they are either silent or missense variants present also in control individuals [<xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>]. Two nucleotide normal variants have been identified in the non-coding region of <italic toggle="yes">TFR2</italic> [<xref ref-type="bibr" rid="tfr2.REF.meregalli.2000.532">Meregalli et al 2000</xref>, <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>]. A <italic toggle="yes">TFR2</italic> intronic SNP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7385804">rs7385804</ext-link>) was associated with physiologic serum iron modification in genome-wide association studies [<xref ref-type="bibr" rid="tfr2.REF.pichler.2011.1232">Pichler et al 2011</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> Sixteen causal variants have been reported; most are rare or private [<xref ref-type="bibr" rid="tfr2.REF.roetto.2002.465">Roetto et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.lee.2006.102">Lee &#x00026; Barton 2006</xref>, <xref ref-type="bibr" rid="tfr2.REF.hsiao.2007.303">Hsiao et al 2007</xref>, <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>, <xref ref-type="bibr" rid="tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami et al 2008</xref>, <xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>] (see <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">Table 2</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>The most frequent variant is p.Tyr250Ter, identified in four different Italian families [<xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al 2000</xref>, <xref ref-type="bibr" rid="tfr2.REF.piperno.2004.359">Piperno et al 2004</xref>] who live in the same geographic area and thus may be distantly related.</p>
            </list-item>
            <list-item>
              <p>p.Arg30ProfsTer31 has been found in a single large Italian family [<xref ref-type="bibr" rid="tfr2.REF.roetto.2002.465">Roetto et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>p.Met172Lys has been found in two unrelated Italian families [<xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.majore.2006.ecr33">Majore et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>A recurrent pathogenic variant is a deletion of 12 nucleotides in a 12-nucleotide repeat in exon 16, which results in a four-amino acid deletion p.Ala621_Gln624del (see <xref ref-type="fig" rid="tfr2.F1">Figure 1</xref>) [<xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al 2002</xref>, <xref ref-type="bibr" rid="tfr2.REF.hattori.2003.154">Hattori et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>The private pathogenic variant p.Arg105Ter was characterized in two affected young siblings from France [<xref ref-type="bibr" rid="tfr2.REF.le_gac.2004.674">Le Gac et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Two novel variants (p.Leu490Arg and p.Ser556AlafsTer6) were characterized in Japanese individuals [<xref ref-type="bibr" rid="tfr2.REF.koyama.2005.302">Koyama et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>p.Gln317Ter was reported in association with <italic toggle="yes">HFE</italic> p.Cys282Tyr and p.His63Asp compound heterozygosity in two siblings with a juvenile phenotype and in association with wild-type <italic toggle="yes">HFE</italic> in a brother with a classic type of HHC [<xref ref-type="bibr" rid="tfr2.REF.pietrangelo.2005.470">Pietrangelo et al 2005</xref>]. See <xref ref-type="sec" rid="tfr2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref> for <italic toggle="yes">HFE</italic> variant references.</p>
            </list-item>
            <list-item>
              <p>Two novel <italic toggle="yes">TFR2</italic> variants (p.Arg396Ter and p.Gly792Arg) associated with an already characterized polymorphic variant (p.Arg455Gln) [<xref ref-type="bibr" rid="tfr2.REF.hofmann.2002.1099">Hofmann et al 2002</xref>] have been found in a single Scottish individual.</p>
            </list-item>
            <list-item>
              <p>A new missense variant has been characterized in a Taiwanese woman with the disease [<xref ref-type="bibr" rid="tfr2.REF.hsiao.2007.303">Hsiao et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p>In an Italian pathogenic variant study, one subject compound heterozygous for two new variants (p.Asn411del and p.Ala444Thr) together with two siblings homozygous for a new causal variant (c.2137-1G&#x0003e;A) have been recently identified [<xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>A combination of the known variant (p.Arg396Ter) and a new variant (c. 1538-2 A&#x0003e;G) in compound heterozygosity has been identified in a young woman of Italian descent [<xref ref-type="bibr" rid="tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>Screening of an iron-overloaded population identified a novel missense variant (p.Phe280Leu) in compound heterozygosity with the <italic toggle="yes">HFE</italic> His63Asp variant [<xref ref-type="bibr" rid="tfr2.REF.mendes.2009.229">Mendes et al 2009</xref>]. Its causal effect is not demonstrated, but the variant involves a highly conserved amino acid.</p>
            </list-item>
            <list-item>
              <p>A new splicing variant that causes the skipping of <italic toggle="yes">TFR2</italic> exon 4 has been identified at the homozygous state in a 47-year-old woman with iron overload [<xref ref-type="bibr" rid="tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</xref>].</p>
            </list-item>
          </list>
          <p>For more information, see <related-object source-id="gene" document-id="tfr2" object-id="tfr2.molgen.TA">Table A</related-object> and <xref ref-type="fig" rid="tfr2.F1">Figure 1</xref>.</p>
          <table-wrap id="tfr2.T.selected_tfr2_allelic_variants" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">TFR2</italic> Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  <th id="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_1" rowspan="9" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.97C&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His33Asn</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_4" rowspan="25" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=110227854">NM_003227.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=33589848">NP_003218.2</ext-link>
                  </td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al [2008]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.224C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala75Val</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2003.1981">Biasiotto et al [2003]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.473+49C&#x0003e;A<break/>(IVS3+49)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al [2008]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1851C&#x0003e;T<break/>(1878C&#x0003e;T)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=) <sup>2</sup><break/>(Ala617Ala)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.meregalli.2000.532">Meregalli et al [2000]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.714C&#x0003e;G</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile238Met</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1364G&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg455Gln</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.hofmann.2002.1099">Hofmann et al [2002]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1770C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)<break/>(Asp590Asp)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1851C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)<break/> (Ala617Ala)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2228C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala743Val</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2001.285">Lee et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_1" rowspan="16" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.64G&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val22Ile</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2003.1981">Biasiotto et al [2003]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.88_89insC<break/>(ins88C)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg30ProfsTer31<break/>(E60Ter)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.313C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg105Ter<break/>(E60Ter)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.le_gac.2004.674">Le Gac et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.515T&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met172Lys</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2137-1G&#x0003e;A<break/>(IVS17+5636)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al [2008]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.750C&#x0003e;G</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr250Ter</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al [2000]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.949C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln317Ter</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.pietrangelo.2005.470">Pietrangelo et al [2005]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1186C&#x0003e;T</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg396Ter</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2006.102">Lee &#x00026; Barton [2006]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1231_1233del</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn411del</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al [2008]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1330G&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala444Thr</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.biasiotto.2008.309">Biasiotto et al [2008]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1403G&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg468His<break/>(Arg481His)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.hsiao.2007.303">Hsiao et al [2007]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1469T&#x0003e;G</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu490Arg</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.koyama.2005.302">Koyama et al [2005]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1665delC</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser556AlafsTer6<break/>(Val561Ter)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.koyama.2005.302">Koyama et al [2005]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1861_1872del12</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala621_Gln624del<break/>(AVAQ621-624del)</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.girelli.2002.1295">Girelli et al [2002]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2069A&#x0003e;C</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln690Pro</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2374G&#x0003e;A</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly792Arg</td>
                  <td headers="hd_h_tfr2.T.selected_tfr2_allelic_variants_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">
                    <xref ref-type="bibr" rid="tfr2.REF.lee.2006.102">Lee &#x00026; Barton [2006]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="tfr2.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="tfr2.TF.2.2">
                <label>2. </label>
                <p>The designation p.(=) means that no effect on protein level is expected.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> TfR2 is a type II transmembrane glycoprotein characterized by short intracellular and transmembrane domains and a large extracellular domain. The TfR2 full-length transcript (the alpha form) originates an 801-amino acid transmembrane protein. Residues 1-80 correspond to the cytoplasmic domain, residues 81-104 correspond to the transmembrane, and amino acids 105-801 correspond to the extracellular domain. Cysteines 89-98 and 108-111 are involved in disulfide bonds, likely responsible for <italic toggle="yes">TFR2</italic> homodimerization. A YQRV amino acid motif in the cytoplasmic domain, similar to the internalization signal (YTRF) of transferrin receptor (TFRC), could have the same function.</p>
          <p>TfR2 is highly expressed in hepatoma (HEPG2) and in erythroleukemia cell lines (K562) [<xref ref-type="bibr" rid="tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</xref>]. It is expressed in the liver, especially in the hepatocytes, and at low levels in Kuppfer cells [<xref ref-type="bibr" rid="tfr2.REF.zhang.2004.1509">Zhang et al 2004</xref>]. Recently it has been shown that TfR2 protein is expressed in erythroid cells in mice and humans and that TfR2 protein interacts with the erythropoietin receptor [<xref ref-type="bibr" rid="tfr2.REF.forejtnikov_.2010.5357">Forejtnikov&#x000e0; et al 2010</xref>]. It remains to be determined if this erythroid expression has some relationship with hepcidin inhibition in erythroid expansion.</p>
          <p>Alpha-TfR2 binds and internalizes transferrin. However, binding occurs at low affinity (25- to 30-fold lower) [<xref ref-type="bibr" rid="tfr2.REF.kawabata.2000.16618">Kawabata et al 2000</xref>], as compared to that of the transferrin receptor (TFRC). Alpha-TfR2 protein shows significant amino acid homology with TFRC and the prostate-specific membrane antigen (PSMA), especially in the extracellular portion [<xref ref-type="bibr" rid="tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</xref>]. Expression of TfR2 is in fact reported in several cancer cell lines and primary tumor cells [<xref ref-type="bibr" rid="tfr2.REF.calzolari.2009.243">Calzolari et al 2009</xref>, <xref ref-type="bibr" rid="tfr2.REF.calzolari.2010.123">Calzolari et al 2010</xref>]</p>
          <p>Beta-TfR2 lacks the cytoplasmic and transmembrane domains and could be an intracellular protein.</p>
          <p><italic toggle="yes">TFR2</italic> has no IRE elements in its 5' or 3' UTR and is not transcriptionally regulated by iron. <italic toggle="yes">TFR2</italic> does not bind <italic toggle="yes">HFE</italic> in vitro because residues involved in <italic toggle="yes">HFE</italic> binding in TFRC are not conserved in <italic toggle="yes">TFR2</italic> [<xref ref-type="bibr" rid="tfr2.REF.west.2000.38135">West et al 2000</xref>]. <italic toggle="yes">TFR2</italic> is also expressed by early erythroid progenitors but not by bone marrow precursors [<xref ref-type="bibr" rid="tfr2.REF.calzolari.2004.629">Calzolari et al 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.forejtnikov_.2010.5357">Forejtnikov&#x000e0; et al 2010</xref>].</p>
          <p><italic toggle="yes">TFR2</italic>-encoded protein in HepG2 cell line is stabilized by diferric transferrin, which increases <italic toggle="yes">TFR2</italic>-encoded protein half-life [<xref ref-type="bibr" rid="tfr2.REF.johnson.2004.4287">Johnson &#x00026; Enns 2004</xref>, <xref ref-type="bibr" rid="tfr2.REF.robb.2004.4294">Robb &#x00026; Wessling-Resnick 2004</xref>]. In addition, <italic toggle="yes">TFR2</italic> mediates a biphasic pattern of transferrin uptake associated with ligand delivery to multivesicular bodies [<xref ref-type="bibr" rid="tfr2.REF.robb.2004.c1769">Robb et al 2004</xref>]. Tfr2 stabilization by transferrin reduces Tfr2 lysosomal degradation and directs <italic toggle="yes">TFR2</italic> toward the recycling endosome [<xref ref-type="bibr" rid="tfr2.REF.johnson.2007.743">Johnson et al 2007</xref>].</p>
          <p>The cytoplasmic domain is that involved in membrane stabilization after TF binding [<xref ref-type="bibr" rid="tfr2.REF.chen.2007.6201">Chen &#x00026; Enns 2007</xref>]. In the present model, TfR2 stabilized on plasma membrane binds HFE to activate hepcidin [<xref ref-type="bibr" rid="tfr2.REF.gao.2009.217">Gao et al 2009</xref>] but the molecular mechanism remain unclear.</p>
          <p>Animal models of the disease have been developed:</p>
          <list list-type="bullet">
            <list-item>
              <p>A <italic toggle="yes">Tfr2</italic>-deficient mouse homozygous for <italic toggle="yes">Tfr2</italic><sup>Y245X</sup> [<xref ref-type="bibr" rid="tfr2.REF.fleming.2002.10653">Fleming et al 2002</xref>], a pathogenic variant orthologous to the human p.Tyr250Ter [<xref ref-type="bibr" rid="tfr2.REF.camaschella.2000.14">Camaschella et al 2000</xref>], the <italic toggle="yes">Tfr2</italic>-knockout mouse [<xref ref-type="bibr" rid="tfr2.REF.wallace.2005.980">Wallace et al 2005</xref>], and a conditional hepatic knock out [<xref ref-type="bibr" rid="tfr2.REF.wallace.2007.301">Wallace et al 2007</xref>]. All these mice show iron overload in liver and other organs with the spleen relatively free of iron as in the human disorder [<xref ref-type="bibr" rid="tfr2.REF.fleming.2002.10653">Fleming et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>The <italic toggle="yes">Tfr2</italic>-null (knockout) shows significant iron overload and is unable to increase hepcidin in response to iron [<xref ref-type="bibr" rid="tfr2.REF.wallace.2005.980">Wallace et al 2005</xref>].</p>
            </list-item>
          </list>
          <p>More recently other models have been developed: a murine line with selective inactivation of the <italic toggle="yes">Tfr2</italic>-beta isoform (KI mice), <italic toggle="yes">Tfr2</italic> knock out animals within the identical genetic background, and a model with inactivation of both Tfr2-alpha and -beta isoforms in the liver and Tfr2-beta isoform in the other tissues (LCKO-KI) The latter animals develop earlier and more severe iron overload than KO, while KI animals have normal iron parameters and iron gene expression, but develop severe iron overload in the spleen [<xref ref-type="bibr" rid="tfr2.REF.roetto.2010.3382">Roetto et al 2010</xref>]. Simultaneous inactivation of <italic toggle="yes">Tfr2</italic> and <italic toggle="yes">Hfe</italic> in mice induces a more severe iron overload and a more marked hepcidin deficiency than inactivating the single genes [<xref ref-type="bibr" rid="tfr2.REF.wallace.2009.1992">Wallace et al 2009</xref>]. This suggests some additive function for the two genes in hepcidin control [<xref ref-type="bibr" rid="tfr2.REF.wallace.2009.1992">Wallace et al 2009</xref>].</p>
          <p><bold>Abnormal gene product.</bold> The pathogenic variants produce a truncated protein or an abnormally structured protein (e.g., p.Ala621_Gln624del, p.Leu490Arg, p.Gln690Pro). The pathogenic variant p.Met172Lys is of interest because it causes a missense in the alpha form but alters methionine, which is the putative initiation codon of beta <italic toggle="yes">TFR2</italic> [<xref ref-type="bibr" rid="tfr2.REF.roetto.2001.2555">Roetto et al 2001</xref>, <xref ref-type="bibr" rid="tfr2.REF.majore.2006.ecr33">Majore et al 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="tfr2.References">
        <title>References</title>
        <sec id="tfr2.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="tfr2.Literature_Cited.reflist0">
            <ref id="tfr2.REF.adams.2010.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>How I treat hemochromatosis.</article-title>
                <source>Blood.</source>
                <volume>116</volume>
                <fpage>317</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">20308595</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.aguilarmartinez.2001a.290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aguilar-Martinez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esculie-Coste</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bismuth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giansily-Blaizot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larrey</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schved</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <year>2001a</year>
                <article-title>Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>27</volume>
                <fpage>290</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11358390</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.aguilarmartinez.2001b.836">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aguilar-Martinez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bismuth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picot</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thelcide</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pageaux</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanc</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanc</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schved</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larrey</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2001b</year>
                <article-title>Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause?</article-title>
                <source>Gut</source>
                <volume>48</volume>
                <fpage>836</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">11358905</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.asberg.2001.1108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Asberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hveem</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorstensen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellekjter</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kannelonning</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fjosne</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halvorsen</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smethurst</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sagen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjerve</surname>
                    <given-names>KS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.</article-title>
                <source>Scand J Gastroenterol</source>
                <volume>36</volume>
                <fpage>1108</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">11589387</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.barton.2001.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivers</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>RT</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Transferrin receptor-2 (TFR2) mutation Y250X in Alabama caucasian and African American subjects with and without primary iron overload.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>27</volume>
                <fpage>279</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">11358388</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.barton.2007.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>39</volume>
                <fpage>206</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">17490902</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.beutler.2003.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felitti</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelbart</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waalen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vulpe</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>31</volume>
                <fpage>305</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14636643</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.beutler.2002.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felitti</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koziol</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelbart</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Penetrance of 845G&#x0003e;A (C282Y) HFE hereditary haemochromatosis mutation in the USA.</article-title>
                <source>Lancet</source>
                <volume>359</volume>
                <fpage>211</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11812557</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.biasiotto.2003.1981">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biasiotto</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belloli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruggeri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanella</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corrado</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobbi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albertini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arosio</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload.</article-title>
                <source>Clin Chem</source>
                <volume>49</volume>
                <fpage>1981</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14633868</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.biasiotto.2008.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biasiotto</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forni</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polotti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zecchina</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arosio</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>New TFR2 mutations in young Italian patients with hemochromatosis.</article-title>
                <source>Haematologica</source>
                <volume>93</volume>
                <fpage>309</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">18245657</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.calzolari.2009.243">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calzolari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deaglio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maldi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassoni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malavasi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>TfR2 expression in human colon carcinomas.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <volume>43</volume>
                <fpage>243</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19729324</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.calzolari.2010.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calzolari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larocca</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deaglio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finisguerra</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raggi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci-Vitani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierconti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malavasi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Maria</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallini</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Transferrin receptor 2 is frequently and highly expressed in glioblastomas.</article-title>
                <source>Transl Oncol.</source>
                <volume>3</volume>
                <fpage>123</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">20360937</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.calzolari.2004.629">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calzolari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deaglio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sposi</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morsilli</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabbianelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malavasi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peschle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Transferrin receptor 2 protein is not expressed in normal erythroid cells.</article-title>
                <source>Biochem J.</source>
                <volume>381</volume>
                <fpage>629</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15084147</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.camaschella.2000.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majorano</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.</article-title>
                <source>Nat Genet</source>
                <volume>25</volume>
                <fpage>14</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10802645</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.camaschella.2009.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poggiali</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Rare types of genetic hemochromatosis.</article-title>
                <source>Acta Haematol.</source>
                <volume>122</volume>
                <fpage>140</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19907151</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.carneiro.2004.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carneiro</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilela</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandes</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ara&#x000fa;jo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baffa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elias</surname>
                    <given-names>J</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>St Pierre</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angulo</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Covas</surname>
                    <given-names>DT</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>In vivo tissue characterization using magnetic techniques.</article-title>
                <source>Neurol Clin Neurophysiol.</source>
                <volume>2004</volume>
                <fpage>85</fpage>
                <pub-id pub-id-type="pmid">16012653</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.chen.2007.6201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The Cytoplasmic domain of transferrin receptor 2 dictates its stability and response to holo-transferrin in Hep3B cells.</article-title>
                <source>J Biol Chem.</source>
                <volume>282</volume>
                <fpage>6201</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17202145</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.de_gobbi.2001.243">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barilaro</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sbaiz</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>TFR2 Y250X mutation in Italy.</article-title>
                <source>Br J Haematol</source>
                <volume>114</volume>
                <fpage>243</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11472377</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.de_gobbi.2002.973">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papanikolaou</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Politou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockitch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargion</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Natural history of juvenile haemochromatosis.</article-title>
                <source>Br J Haematol</source>
                <volume>117</volume>
                <fpage>973</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12060140</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.drakesmith.2005.1092">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Drakesmith</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schimanski</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ormerod</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merryweather-Clarke</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viprakasit</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetland</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastin</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinthammitr</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Townsend</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.</article-title>
                <source>Blood</source>
                <volume>106</volume>
                <fpage>1092</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15831700</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.european_association_for_the_study_of_the_liver.2010.3">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>European Association for the Study of the Liver</collab>
                </person-group>
                <year>2010</year>
                <article-title>EASL clinical practice guidelines for HFE hemochromatosis.</article-title>
                <source>J Hepatol.</source>
                <volume>53</volume>
                <fpage>3</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">20471131</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.fleming.2002.10653">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmann</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migas</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waheed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeffler</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawabata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Britton</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sly</surname>
                    <given-names>WS</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis.</article-title>
                <source>Proc Natl Acad Sci USA</source>
                <volume>99</volume>
                <fpage>10653</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12134060</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.forejtnikov_.2010.5357">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Forejtnikov&#x000e0;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieillevoye</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zermati</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegrino</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guihard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudry</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayeux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verdier</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis.</article-title>
                <source>Blood</source>
                <volume>116</volume>
                <fpage>5357</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">20826723</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.gao.2009.217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression.</article-title>
                <source>Cell Metab.</source>
                <volume>9</volume>
                <fpage>217</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">19254567</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.gandon.2004.357">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gandon</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivie</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guyader</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aube</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebille</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deugnier</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Non-invasive assessment of hepatic iron stores by MRI.</article-title>
                <source>Lancet</source>
                <volume>363</volume>
                <fpage>357</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">15070565</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.g_rolami.2008.e45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000e9;rolami</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Gac</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nezri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg&#x000e9;-Lefranc</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000e9;rec</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Early-onset haemochromatosis caused by a novel combination of TFR2 mutations(p.R396X/c.1538-2 A&#x0003e;G) in a woman of Italian descent.</article-title>
                <source>Haematologica.</source>
                <volume>93</volume>
                <fpage>e45</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18450729</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.girelli.2002.1295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Girelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bozzini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daraio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombari</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corrocher</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.</article-title>
                <source>Gastroenterology</source>
                <volume>122</volume>
                <fpage>1295</fpage>
                <lpage>302</lpage>
                <pub-id pub-id-type="pmid">11984516</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.girelli.2011.500">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Girelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trombini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Busti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campostrini</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelucchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westerman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.</article-title>
                <source>Haematologica.</source>
                <volume>96</volume>
                <fpage>500</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21173098</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.glockner.1998.1060">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glockner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schattevoy</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boright</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenthal</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Large-scale sequencing of two regions in human chromosome 7q22: analysis of 650 kb of genomic sequence around the EPO and CUTL1 loci reveals 17 genes.</article-title>
                <source>Genome Res</source>
                <volume>8</volume>
                <fpage>1060</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">9799793</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.gordeuk.2003.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caleffi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corradini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castro</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onyekwere</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kittles</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignatti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montosi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garuti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangaidzo</surname>
                    <given-names>IT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomo</surname>
                    <given-names>ZA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moyo</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouault</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacPhail</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>31</volume>
                <fpage>299</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">14636642</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.guyader.1998.929">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guyader</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquelinet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moirand</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turlin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendler</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaperon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brissot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deugnier</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.</article-title>
                <source>Gastroenterology</source>
                <volume>115</volume>
                <fpage>929</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">9753496</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.hattori.2003.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakusawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harashima</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanae</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawanaka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshioka</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis.</article-title>
                <source>Hepatol Res</source>
                <volume>26</volume>
                <fpage>154</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12809944</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.hayashi.2006.1107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakusawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motonishi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inagaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Genetic background of primary iron overload syndromes in Japan.</article-title>
                <source>Intern Med.</source>
                <volume>45</volume>
                <fpage>1107</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">17106152</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.hentze.2010.24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hentze</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muckenthaler</surname>
                    <given-names>MU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Two to tango: regulation of Mammalian iron metabolism.</article-title>
                <source>Cell.</source>
                <volume>142</volume>
                <fpage>24</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">20603012</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.hofmann.2002.1099">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hofmann</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>XJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ajioka</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeffler</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis.</article-title>
                <source>Blood</source>
                <volume>100</volume>
                <fpage>1099</fpage>
                <lpage>100</lpage>
                <pub-id pub-id-type="pmid">12150153</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.hsiao.2007.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hsiao</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuo</surname>
                    <given-names>KK</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis.</article-title>
                <source>J Hepatol.</source>
                <volume>47</volume>
                <fpage>303</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17562347</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.johnson.2007.743">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murchison</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway.</article-title>
                <source>Mol Biol Cell</source>
                <volume>18</volume>
                <fpage>743</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">17182845</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.johnson.2004.4287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Diferric transferrin regulates transferrin receptor 2 protein stability.</article-title>
                <source>Blood.</source>
                <volume>104</volume>
                <fpage>4287</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">15319290</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.kawabata.2005.376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kawabata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gui</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moon</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saitoh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Kelly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Umehara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wano</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeffler</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>376</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">15345587</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.kawabata.2000.16618">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kawabata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vuong</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeffler</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo.</article-title>
                <source>J Biol Chem</source>
                <volume>275</volume>
                <fpage>16618</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">10748106</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.kawabata.1999.20826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kawabata</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vuong</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gombart</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeffler</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family.</article-title>
                <source>J Biol Chem</source>
                <volume>274</volume>
                <fpage>20826</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10409623</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.koyama.2005.302">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koyama</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakusawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshioka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kozuru</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takayamam</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mabuchi</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.</article-title>
                <source>Haematologica</source>
                <volume>90</volume>
                <fpage>302</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15749661</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.le_gac.2004.674">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Le Gac</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mons</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacolot</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scotet</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000e9;rec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000e9;bourg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent.</article-title>
                <source>Br J Haematol.</source>
                <volume>125</volume>
                <fpage>674</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15147384</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.lee.2006.102">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hemochromatosis and severe iron overload associated with compound heterozygosity for TFR2 R455Q and two novel mutations TFR2 R396X and G792R.</article-title>
                <source>Acta Haematol.</source>
                <volume>115</volume>
                <fpage>102</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16424658</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.lee.2001.285">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halloran</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutation analysis of the transferrin receptor-2 gene in patients with iron overload.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>27</volume>
                <fpage>285</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11358389</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.majore.2006.ecr33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Majore</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Binni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuppia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tafuri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bernardo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grammatico</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload.</article-title>
                <source>Haematologica.</source>
                <volume>91</volume>
                <fpage>ECR33</fpage>
                <pub-id pub-id-type="pmid">16923517</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.mattman.2002.1075">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mattman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huntsman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockitch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langlois</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buskard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ralston</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butterfield</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodrigues</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porto</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Sousa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatcher</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation.</article-title>
                <source>Blood</source>
                <volume>100</volume>
                <fpage>1075</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12130528</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.mcnamara.2005.1855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McNamara</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacPhail</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Ferroportin (Q248H) mutations in African families with dietary iron overload.</article-title>
                <source>J Gastroenterol Hepatol</source>
                <volume>20</volume>
                <fpage>1855</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16336444</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.mendes.2009.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mendes</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pican&#x000e7;o</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomes</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerqueira</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Correia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esteves</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faustino</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes.</article-title>
                <source>Ann Hematol.</source>
                <volume>88</volume>
                <fpage>229</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">18762941</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.meregalli.2000.532">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meregalli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellagatti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bissolotti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fracanzani</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargion</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sampietro</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Molecular analysis of the TFR2 gene: report of a novel polymorphism (1878C&#x0003e;T).</article-title>
                <source>Hum Mutat</source>
                <volume>16</volume>
                <fpage>532</fpage>
                <pub-id pub-id-type="pmid">11102989</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.montosi.2001.619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Montosi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donovan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garuti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignatti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassanelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trenor</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.</article-title>
                <source>J Clin Invest</source>
                <volume>108</volume>
                <fpage>619</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11518736</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.nemeth.2005.1803">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hepcidin is decreased in TFR2-Hemochromatosis.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>1803</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15486069</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.njajou.2001.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Njajou</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaessen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berghuis</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dongen</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breuning</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snijders</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutten</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandkuijl</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Duijn</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heutink</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.</article-title>
                <source>Nat Genet</source>
                <volume>28</volume>
                <fpage>213</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11431687</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.pelucchi.2009.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pelucchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trombini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coletti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pozzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paolini</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barisani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2.</article-title>
                <source>Haematologica.</source>
                <volume>94</volume>
                <fpage>276</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19144662</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.phatak.2010.1671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phatak</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brissot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wurster</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonkovsky</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malfertheiner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoelzel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremmel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.</article-title>
                <source>Hepatology.</source>
                <volume>52</volume>
                <fpage>1671</fpage>
                <lpage>779</lpage>
                <pub-id pub-id-type="pmid">20814896</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.pichler.2011.1232">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pichler</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minelli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanna</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwienbacher</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naitza</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porcu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pattaro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Busonero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maschio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melville</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grazia Piras</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guralnik</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bandinelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aigner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wroblewski</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marroni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theurl</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gnewuch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schadt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitterer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlessinger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrucci</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witcher</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hicks</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pramstaller</surname>
                    <given-names>PP</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>20</volume>
                <fpage>1232</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21208937</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.pietrangelo.2005.470">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caleffi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henrion</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corradini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulaksiz</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremmel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreone</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garuti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes.</article-title>
                <source>Gastroenterology</source>
                <volume>128</volume>
                <fpage>470</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15685557</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.pietrangelo.2010.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.</article-title>
                <source>Gastroenterology</source>
                <volume>139</volume>
                <fpage>393</fpage>
                <lpage>408</lpage>
                <pub-id pub-id-type="pmid">20542038</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.piperno.2004.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelucchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corengia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daraio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload.</article-title>
                <source>Haematologica</source>
                <volume>89</volume>
                <fpage>359</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15020277</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.ricerca.2009.494">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ricerca</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radio</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marinis</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bernardo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sacco</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grammatico</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majore</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Natural history of TFR2-related hereditary hemochromatosis in a 47-yr-old Italian patient.</article-title>
                <source>Eur J Haematol.</source>
                <volume>83</volume>
                <fpage>494</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19549277</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.riva.2004.370">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riva</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bovo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelucchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arosio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvioni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vergani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Type 3 hemochromatosis and beta-thalassemia trait.</article-title>
                <source>Eur J Haematol</source>
                <volume>72</volume>
                <fpage>370</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15059075</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.rivers.2007.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rivers</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speechley</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snively</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leiendecker-Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Press</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dawkins</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reboussin</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>38</volume>
                <fpage>247</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">17276706</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.robb.2004.4294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robb</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wessling-Resnick</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Regulation of transferrin receptor 2 protein levels by transferrin.</article-title>
                <source>Blood.</source>
                <volume>104</volume>
                <fpage>4294</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15319276</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.robb.2004.c1769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robb</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ericsson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wessling-Resnick</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Transferrin receptor 2 mediates a biphasic pattern of transferrin uptake associated with ligand delivery to multivesicular bodies.</article-title>
                <source>Am J Physiol Cell Physiol</source>
                <volume>287</volume>
                <fpage>C1769</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">15317665</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.roetto.2002.465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daraio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porporato</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Hemochromatosis due to mutations in transferrin receptor 2.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>29</volume>
                <fpage>465</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">12547237</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.roetto.2010.3382">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Cunto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegrino</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirsch</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzolino</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bondi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defilippi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carturan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miniscalco</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riondato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cilloni</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silengo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altruda</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saglio</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues.</article-title>
                <source>Blood</source>
                <volume>115</volume>
                <fpage>3382</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20179178</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.roetto.1999.1388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cicilano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Ascola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelante</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Juvenile hemochromatosis locus maps to chromosome 1q.</article-title>
                <source>Am J Hum Genet</source>
                <volume>64</volume>
                <fpage>1388</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10205270</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.roetto.2001.2555">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.</article-title>
                <source>Blood</source>
                <volume>97</volume>
                <fpage>2555</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">11313241</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.schimanski.2005.4096">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schimanski</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drakesmith</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merryweather-Clarke</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viprakasit</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetland</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastin</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinthammitr</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Townsend</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>4096</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">15692071</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.st_pierre.2005.855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St Pierre</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chua-anusorn</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffrey</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pootrakul</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robins</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindeman</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>855</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15256427</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.wallace.2007.4690">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramaniam</surname>
                    <given-names>VN</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Non-HFE haemochromatosis.</article-title>
                <source>World J Gastroenterol</source>
                <volume>13</volume>
                <fpage>4690</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17729390</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.wallace.2005.980">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summerville</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lusby</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramaniam</surname>
                    <given-names>VN</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin.</article-title>
                <source>Gut</source>
                <volume>54</volume>
                <fpage>980</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15951546</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.wallace.2007.301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summerville</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramaniam</surname>
                    <given-names>VN</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload.</article-title>
                <source>Gastroenterology</source>
                <volume>132</volume>
                <fpage>301</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">17241880</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.wallace.2009.1992">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summerville</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crampton</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazer</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramaniam</surname>
                    <given-names>VN</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload.</article-title>
                <source>Hepatology.</source>
                <volume>50</volume>
                <fpage>1992</fpage>
                <lpage>2000</lpage>
                <pub-id pub-id-type="pmid">19824072</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.west.2000.38135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>AP</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellers</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjorkman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE.</article-title>
                <source>J Biol Chem</source>
                <volume>275</volume>
                <fpage>38135</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11027676</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.whitington.2004.1690">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whitington</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hibbard</surname>
                    <given-names>JU</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis.</article-title>
                <source>Lancet.</source>
                <volume>364</volume>
                <fpage>1690</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15530630</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.zhang.2004.1509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiong</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes.</article-title>
                <source>Blood</source>
                <volume>103</volume>
                <fpage>1509</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">14563638</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="tfr2.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="tfr2.Suggested_Reading.reflist0">
            <ref id="tfr2.REF.beutler.2006.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hemochromatosis: genetics and pathophysiology.</article-title>
                <source>Annu Rev Med</source>
                <volume>57</volume>
                <fpage>331</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">16409153</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.camaschella.2005.3710">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders.</article-title>
                <source>Blood</source>
                <volume>106</volume>
                <fpage>3710</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16030190</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.drake.2007.g323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Drake</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbison</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delima</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chua</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leedman</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trinder</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3.</article-title>
                <source>Am J Physiol Gastrointest Liver Physiol</source>
                <volume>292</volume>
                <fpage>G323</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16935854</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.merle.2007.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merle</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theilig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fein</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehrke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kallinowski</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riedel</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachmann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremmel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulaksiz</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Localization of the iron-regulatory proteins hemojuvelin and transferrin receptor 2 to the basolateral membrane domain of hepatocytes.</article-title>
                <source>Histochem Cell Biol</source>
                <volume>127</volume>
                <fpage>221</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16932966</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.pietrangelo.2005.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Non-HFE hemochromatosis.</article-title>
                <source>Semin Liver Dis</source>
                <volume>25</volume>
                <fpage>450</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">16315138</pub-id>
              </element-citation>
            </ref>
            <ref id="tfr2.REF.roetto.2005.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis.</article-title>
                <source>Best Pract Res Clin Haematol</source>
                <volume>18</volume>
                <fpage>235</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">15737887</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="tfr2.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="tfr2.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>9 June 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 August 2008 (cd) Revision: prenatal diagnosis available clinically</p>
            </list-item>
            <list-item>
              <p>15 May 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>7 August 2006 (ar) Revision: change in mutation nomenclature from AVAQ594-597del to AVAQ621-624del</p>
            </list-item>
            <list-item>
              <p>5 December 2005 (ar) Revision: targeted mutation analysis clinically available; mutation scanning no longer available</p>
            </list-item>
            <list-item>
              <p>29 August 2005 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>1 February 2005 (ar) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="tfr2.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Schematic representation of the localization of <italic toggle="yes">TFR2</italic> pathogenic variants. Causal variants are illustrated in bold above the gene; exonic normal variants are marked below the gene (see <xref ref-type="table" rid="tfr2.T.selected_tfr2_allelic_variants">Table 2</xref>). The two alternatively spliced <italic toggle="yes">TFR2</italic> transcripts are also shown. Alternative transcription start sites are indicated by the dotted arrow lines.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tfr2-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
